JP2014509605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509605A5 JP2014509605A5 JP2013558513A JP2013558513A JP2014509605A5 JP 2014509605 A5 JP2014509605 A5 JP 2014509605A5 JP 2013558513 A JP2013558513 A JP 2013558513A JP 2013558513 A JP2013558513 A JP 2013558513A JP 2014509605 A5 JP2014509605 A5 JP 2014509605A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- cell antigen
- unwanted
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 claims 62
- 239000000427 antigen Substances 0.000 claims 34
- 102000038129 antigens Human genes 0.000 claims 34
- 108091007172 antigens Proteins 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 31
- 230000027455 binding Effects 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 108090001123 antibodies Proteins 0.000 claims 18
- 102000004965 antibodies Human genes 0.000 claims 18
- 238000003776 cleavage reaction Methods 0.000 claims 17
- 230000001575 pathological Effects 0.000 claims 11
- 229940079593 drugs Drugs 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 4
- 102000027675 major histocompatibility complex family Human genes 0.000 claims 4
- 101710027366 ACVRL1 Proteins 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 102000033147 ERVK-25 Human genes 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- 102100017963 PSCA Human genes 0.000 claims 2
- 101700038464 PSCA Proteins 0.000 claims 2
- 108091005771 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000003211 malignant Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229960005486 vaccines Drugs 0.000 claims 2
- YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 claims 1
- 102100000002 ACVRL1 Human genes 0.000 claims 1
- 102100001249 ALB Human genes 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 102100005830 CD70 Human genes 0.000 claims 1
- 101700017377 CD70 Proteins 0.000 claims 1
- 102100004099 CD74 Human genes 0.000 claims 1
- 101710007476 CD74 Proteins 0.000 claims 1
- 102100019451 CD80 Human genes 0.000 claims 1
- 101700080477 CD80 Proteins 0.000 claims 1
- 102100002212 CXCR4 Human genes 0.000 claims 1
- 101710003734 CXCR4 Proteins 0.000 claims 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims 1
- 108010022830 Cetuximab Proteins 0.000 claims 1
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 101700033006 EGF Proteins 0.000 claims 1
- 102100016627 EPHA2 Human genes 0.000 claims 1
- 102000027776 ERBB3 Human genes 0.000 claims 1
- 101700041204 ERBB3 Proteins 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 229940088598 Enzyme Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101700010580 FLO11 Proteins 0.000 claims 1
- 101710022257 FLT3LG Proteins 0.000 claims 1
- 102100004572 FLT3LG Human genes 0.000 claims 1
- 108010091266 Gemtuzumab Proteins 0.000 claims 1
- 102000010956 Glypicans Human genes 0.000 claims 1
- 108050001154 Glypicans Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 101700040665 IGF Proteins 0.000 claims 1
- 101700074337 IGF1 Proteins 0.000 claims 1
- 108060003940 IL6 Proteins 0.000 claims 1
- 102000009438 IgE Receptors Human genes 0.000 claims 1
- 108010073816 IgE Receptors Proteins 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 229940040461 Lipase Drugs 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 102100001008 MET Human genes 0.000 claims 1
- 108090000028 MMP12 Proteins 0.000 claims 1
- 102100004965 MMP14 Human genes 0.000 claims 1
- 101700056196 MMP14 Proteins 0.000 claims 1
- 101700060512 MMP2 Proteins 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 102100006037 MUC1 Human genes 0.000 claims 1
- 101700052761 MUC1 Proteins 0.000 claims 1
- 102100013927 MUC5AC Human genes 0.000 claims 1
- 101710035006 MUC5AC Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 102100007544 NCAM1 Human genes 0.000 claims 1
- 101700077124 NCAM1 Proteins 0.000 claims 1
- 101700080605 NUC1 Proteins 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 102000004207 Neuropilin-1 Human genes 0.000 claims 1
- 108090000772 Neuropilin-1 Proteins 0.000 claims 1
- 101710018349 PDGFRA Proteins 0.000 claims 1
- 108010001441 Phosphopeptides Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 102100005287 SLC44A4 Human genes 0.000 claims 1
- 108091007272 SLC44A4 Proteins 0.000 claims 1
- 101700001014 SLTM Proteins 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 102100012981 TNFRSF10A Human genes 0.000 claims 1
- 101710030971 TNFRSF10A Proteins 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 230000002494 anti-cea Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- -1 aspartyl Chemical group 0.000 claims 1
- 108010089934 carbohydrase Proteins 0.000 claims 1
- 101710014509 celF Proteins 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 101710031453 groL2 Proteins 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003308 immunostimulating Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 102000004882 lipase Human genes 0.000 claims 1
- 108090001060 lipase Proteins 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 101700006494 nucA Proteins 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 102000002689 toll-like receptors Human genes 0.000 claims 1
- 108020000411 toll-like receptors Proteins 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Claims (38)
- 望まれない細胞の存在を特徴とする病態を予防または治療するための薬剤であって、
（ｉ）前記望まれない細胞への標的が可能である標的化部分と、
（ｉｉ）Ｔ細胞抗原と
を含み、前記望まれない細胞の近傍での前記薬剤中の切断部位の選択的切断により前記標的化部分から前記Ｔ細胞抗原を放出させることができる薬剤。 - 前記Ｔ細胞抗原が、被験体における既存のＴ細胞応答の惹起が可能であるものである、請求項１に記載の薬剤。
- 前記切断部位の選択的切断が、望まれない細胞の近傍および外部での前記Ｔ細胞抗原の放出を可能にする、請求項１または２に記載の薬剤。
- 前記切断部位の選択的切断が、前記望まれない細胞の細胞表面でのまたは付近でのＴ脂肪抗原の放出を可能にする、請求項１〜３のいずれか一項に記載の薬剤。
- 前記標的化部分が、前記望まれない細胞によって発現される物質の特異的結合パートナーである、または被験体への投与後に前記望まれない細胞の近傍に蓄積することができる非特異的分子である、請求項１〜４のいずれか一項に記載の薬剤。
- 前記特異的結合パートナーが、抗体、ホルモン、成長因子、サイトカインもしくは受容体リガンドのいずれかであり、または前記非特異的分子が、ポリエチレングリコール；デキストラン；ポリアミノ酸；非腫瘍特異的タンパク質、例えば免疫グロブリン；アルブミン；もしくはヒドロキシプロピルメチルアクリルアミドのいずれかである、請求項５に記載の薬剤。
- 前記抗体が、Ｈｅｒ２／Ｎｅｕ；ＣＤ２２；ＥｐＣＡＭ（ＣＤ３２６）；ＥＧＦＲ；ＰＭＳＡ；ＣＤ３０；ＣＤ２０；ＣＤ３３；膜ＩｇＥ；ＩｇＥ受容体（ＣＤ２３）、ＣＤ８０；ＣＤ８６；ＣＤ２；ＣＡ１２５；炭酸脱水酵素ＩＸ；ＣＤ７０；ＣＤ７４；ＣＤ５６；ＣＤ４０；ＣＤ１９；ｃ−ｍｅｔ／ＨＧＦＲ；ＴＲＡＩＬ−Ｒ１；ＤＲ５；ＰＤ−１；ＰＤ１Ｌ；ＩＧＦ−１Ｒ；ＶＥＧＦ−Ｒ２；前立腺幹細胞抗原（ＰＳＣＡ）；ＭＵＣ１；ＣａｎＡｇ；メソテリン；Ｐ−カドヘリン；ミオスタチン（ＧＤＦ８）；ＣＲＩＰＴＯ（ＴＤＧＦ１）；ＡＣＶＲＬ１／ＡＬＫ１；ＭＵＣ５ＡＣ；ＣＥＡＣＡＭ；ＳＬＣ４４Ａ４；ＣＤ２／ＣＳ１；ＣＤ１３７；ＣＸＣＲ４；ニューロピリン１；グリピカン；ＨＥＲ３／ＥＧＦＲ；ＰＤＧＦＲａおよびＥｐｈＡ２のいずれかに対して特異的である、請求項６に記載の薬剤。
- 前記抗体が、抗上皮成長因子受容体抗体、例えばセツキシマブ、抗Ｈｅｒ２抗体、抗ＣＤ２０抗体、例えばリツキシマブ、抗ＣＤ２２抗体、例えばイノツズマブ、抗ＣＤ７０抗体、抗ＣＤ３３抗体、例えばｈｐ６７．６またはゲムツズマブ、抗ＭＵＣ１抗体、例えばＧＰ１．４およびＳＭ３、抗ＣＤ４０抗体、抗ＣＤ７４抗体、抗Ｐ−カドヘリン抗体、抗ＥｐＣＡＭ抗体、抗ＣＤ１３８抗体、抗Ｅ−カドヘリン抗体、抗ＣＥＡ抗体および抗ＦＧＦＲ３抗体である、請求項６に記載の薬剤。
- 前記標的化部分が、ＩＬ−２、ＥＧＦ、ＶＥＧＦ、Ｆｌｔ３Ｌ、ＨＧＦ、ＩＧＦ、ＩＬ−６、ＩＬ−４、Ｔｏｌｌ様受容体または黒色腫刺激ホルモン（ＭＳＨ）のいずれかである、請求項６に記載の薬剤。
- Ｔ細胞抗原が、ペプチド、ポリペプチド、ホスホペプチドまたは脂質、例えばリン脂質もしくはスフィンゴ脂質、のいずれかである、請求項１〜９のいずれか一項に記載の薬剤。
- 前記抗原が、ウイルス由来抗原である、請求項１０に記載の薬剤。
- 前記抗原が、水痘帯状疱疹ウイルス、単純ヘルペスウイルス、サイトメガロウイルス、エプスタイン・バーウイルス、アデノウイルス、ライノウイルス、インフルエンザウイルスのいずれかに由来する、または破傷風トキソイドなどのワクチンに由来する、請求項１０または１１に記載の薬剤。
- 前記Ｔ細胞抗原が、ＭＨＣクラスＩ拘束性抗原、ＭＨＣクラスＩＩ拘束性抗原、またはグループ１ＣＤ１分子に結合することができる抗原である、請求項１〜１２のいずれか一項に記載の薬剤。
- 前記切断部位が、酵素、例えば、プロテアーゼ（例えば、システインプロテアーゼ、アスパルチルプロテアーゼ、セリンプロテアーゼ、マトリックスメタロプロテアーゼ、前立腺特異的抗原またはＣＤ１０）、ヌクレアーゼ（例えば、ＤＮａｓｅ）、リパーゼ、リアーゼ、ホスファターゼまたはカルボヒドラーゼのいずれかによって切断可能であり；場合により、前記切断部位が、マトリックスメタロプロテアーゼＭＭＰ２またはＭＭＰ１４によって切断可能である、請求項１〜１３のいずれか一項に記載の薬剤。
- 前記望まれない細胞の存在を特徴とする病態が、腫瘍（良性もしくは悪性）、自己免疫病態（例えば、糖尿病）、心血管疾患、変性疾患、アレルギー性疾患（例えば、喘息）、神経変性疾患、例えばアルツハイマー病、移植患者または感染症のいずれかである、請求項１〜１４のいずれか一項に記載の薬剤。
- 前記望まれない細胞の存在を特徴とする病態が腫瘍であり、前記Ｔ細胞抗原がペプチドであり、および前記Ｔ細胞抗原が、プロテアーゼ切断部位の選択的切断によって放出される、請求項１〜１５のいずれか一項に記載の薬剤。
- 医学に使用するための、請求項１〜１６のいずれか一項に記載の薬剤。
- 請求項１〜１６のいずれか一項に記載の薬剤と医薬的に許容され得る担体、希釈剤または賦形剤とを含む薬学的組成物。
- 望まれない細胞の存在を特徴とする病態を予防または治療するための、被験体に投与するための医薬であって、請求項１〜１６のいずれか一項に記載の薬剤を含む、医薬。
- 前記被験体に前記薬剤を投与する前に、（ｉ）前記被験体のＭＨＣ対立遺伝子、（ｉｉ）Ｔ細胞抗原に対する前記被験体の細胞傷害性Ｔ細胞応答、（ｉｉｉ）前記被験体における前記望まれない細胞の発現プロファイルのいずれか１つを判定する、請求項１９に記載の医薬。
- 前記病態の予防または治療に好適なさらなる治療薬をさらに含む、請求項１９または２０に記載の医薬。
- 望まれない細胞の存在を特徴とする病態の予防または治療において使用するための請求項１〜１６のいずれか一項に記載の薬剤。
- 望まれない細胞の存在を特徴とする病態を予防または治療するための医薬品の製造における請求項１〜１６のいずれか一項に記載の薬剤の使用。
- 望まれない細胞の存在を特徴とする病態の予防または治療において使用するための、（ｉ）請求項１〜１６のいずれか一項に記載の薬剤と（ｉｉ）該病態の予防または治療に好適なさらなる治療薬とを含む組成物。
- 望まれない細胞の存在を特徴とする病態を予防または治療するための医薬品の製造における、（ｉ）請求項１〜１６のいずれか一項に記載の薬剤と（ｉｉ）該病態の予防または治療に好適なさらなる治療薬とを含む組成物の使用。
- （ｉ）請求項１〜１６のいずれか一項に記載の薬剤と（ｉｉ）前記病態の予防または治療に好適なさらなる治療薬とを含む組成物。
- 前記さらなる治療薬が、ワクチン、免疫賦活薬、抗癌剤、本発明の薬剤に対する抗体応答の阻害剤、およびプロテアーゼ阻害剤のうちのいずれか１つ以上である、請求項２１に記載の医薬、請求項２２に記載の薬剤、請求項２３もしくは２５に記載の使用、または請求項２４もしくは２６に記載の組成物。
- 望まれない細胞の存在を特徴とする病態を予防または治療するためのパーツキットであって、（ｉ）前記望まれない細胞への標的化が可能であり、かつ第一の結合パートナーに付けられている標的化部分と、（ｉｉ）前記第一の結合パートナーへの結合が可能である第二の結合パートナーに付けられているＴ細胞抗原とを含み、前記望まれない細胞の近傍における切断部位の前記Ｔ細胞抗原と第二の結合パートナーの間での選択的切断により前記第二の結合パートナーから前記Ｔ細胞抗原を放出させることができるパーツキット。
- （ｉ）望まれない細胞への標的化が可能である標的化部分と、（ｉｉ）Ｔ細胞抗原と、（ｉｉｉ）被験体の（ａ）ＭＨＣ対立遺伝子、（ｂ）Ｔ細胞抗原に対する細胞傷害性Ｔ細胞応答および（ｃ）該被験体における望ましくない細胞の発現プロファイルのうちの１つ以上の評定するための１つ以上の試薬とを含む、パーツキット。
- 望まれない細胞の存在を特徴とする病態を予防または治療するための医薬であって、（ｉ）前記望まれない細胞への標的化が可能であり、かつ第一の結合パートナーに付けられている標的化部分と、（ｉｉ）前記第一の結合パートナーへの結合が可能である第二の結合パートナーに付けられているＴ細胞抗原であって、前記望まれない細胞の近傍における切断部位の前記Ｔ細胞抗原と第二の結合パートナーの間での選択的切断により前記第二の結合パートナーから放出させることができるＴ細胞抗原とを含む医薬。
- 望まれない細胞への標的化が可能であり、かつ第一の結合パートナーに付けられている標的化部分、および前記第一の結合パートナーへの結合が可能である第二の結合パートナーに付けられているＴ細胞抗原であって、前記望まれない細胞の近傍における切断部位の該Ｔ細胞抗原と第二の結合パートナーの間での選択的切断により前記第二の結合パートナーから該Ｔ細胞抗原を放出させることができる、被験体における望まれない細胞を特徴とする病態の予防または治療において使用するための標的化部分およびＴ細胞抗原。
- 望まれない細胞の存在を特徴とする前記病態が、腫瘍（良性もしくは悪性）、自己免疫病態、心血管疾患、変性疾患、糖尿病、アレルギー反応、神経変性疾患、例えばアルツハイマー病、移植患者または感染症のいずれかである、請求項１９〜２１、２７および３０のいずれか一項に記載の医薬、請求項２２または２７に記載の薬剤、請求項２５または２７に記載の使用、請求項２６または２７に記載の組成物、請求項２８に記載のパーツキット、ならびに請求項３１に記載の標的化部分およびＴ細胞抗原。
- 望まれない細胞の存在を特徴とする病態を予防または治療するための薬剤であって、（ｉ）前記望まれない細胞への標的化が可能である標的化部分と、（ｉｉ）Ｔ細胞抗原と、（ｉｉｉ）前記標的化部分とＴ細胞抗原の間に切断可能部位とを含み、前記切断可能部位を前記望まれない細胞の近傍で選択的に切断することができる薬剤。
- （ｉ）Ｔ細胞抗原と（ｉｉ）切断可能部位とを含む分子であって、前記切断可能部位が、望まれない細胞への標的化が可能である標的化部分に該分子を付けることを可能にする連結部分を含有し、および前記切断可能部位を前記望まれない細胞の近傍で選択的に切断することができる分子。
- ペプチド：ＮＬＶＰＭＶＡＴＶＱＫＷＮＫＷＡＬＳＲＡＳＡＬＡＳＡＬＣ（配列番号２８３）、ＮＬＶＰＭＶＡＴＶＱＨＳＳＫＬＱＬＧＧＧＳＧＧＧＧＳＣ（配列番号２８５）、ＮＬＶＰＭＶＡＴＶＱＧＧＧＧＦＧＧＧＧＦＧＧＧＧＦＣ（配列番号２８７）、ＮＬＶＰＭＶＡＴＶＱＫＱＳＲＫＦＶＰＧＧＧＳＧＧＧＧＳＣ（配列番号２８８）、ＮＬＶＰＭＶＡＴＶＱＣＰＧＲＶＶＧＧＧＧＧＳＧＧＧＧＳＣ（配列番号２８９）、ＮＬＶＰＭＶＡＴＶＱＹＬＧＲＳＹＫＶＧＧＧＳＧＧＧＧＳＣ（配列番号２９０）、ＮＬＶＰＭＶＡＴＶＱＧＰＱＧＩＡＳＱＧＧＧＳＧＧＧＧＳＣ（配列番号２９２）、ＮＬＶＰＭＶＡＴＶＱＰＱＧ−ＩＡＧＱＧＧＧＳＧＧＧＧＳＣ（配列番号２９３）、ＮＬＶＰＭＶＡＴＶＱＶＬＫＶＬＫＶＬＫＧＧＧＳＧＧＧＧＳＣ（配列番号２９５）、ＫＴＰＲＶＴＧＧＧＡＭＡＩＰＶＳＬＲＳＧＧＧＧＳＧＧＧＧＳＣ（配列番号２７３）、ＤＤＹＳＮＴＨＳＴＲＹＶＴＩＰＶＳＬＲＳＧＧＧＧＳＧＧＧＧＳＣ（配列番号２７４）、ＲＮＬＶＰＭＶＡＴＶＱＩＰＶＳＬＲＳＧＧＧＧＳＧＧＧＧＳＣ（配列番号２７５）、ＹＶＬＥＥＴＳＶＭＬＩＰＶＳＬＲＳＧＧＧＧＳＧＧＧＧＳＣ（配列番号２７７）、ＮＬＶＰＭＶＡＴＶＱＧＡＬＡＬＡＬＡＬＣ（配列番号２７８）、ＮＬＶＰＭＶＡＴＶＱＧＰＬＧＡＬＡＬＡＬＡＬＡＬＡＬＡＬＡＬＡＬＡＬＡＬＣ（配列番号２７９）、またはＮＬＶＰＭＶＡＴＶＬＰＲＳＡＫＥＬＲＣ（配列番号２８０）、ＣＳＧＧＧＧＳＧＧＧＧＣＰＧＲＶＶＧＧＡＮＬＶＰＭＶＡＴＶ（配列番号２９７）、ＣＳＧＧＧＧＳＧＧＧＧＧＧＲＡＮＬＶＰＭＶＡＴＶ（配列番号２９８）、ＣＳＧＧＧＧＳＧＧＧＧＹＬＧＲＳＹＫＶＡＮＬＶＰＭＶＡＴＶ（配列番号２９９）、ＣＳＧＧＧＧＳＧＧＧＧＳＬＧＲＫＩＱＩＡＮＬＶＰＭＶＡＴＶ（配列番号３００）、ＣＳＧＧＧＧＳＧＧＧＧＬＶＰＲＧＳＡＮＬＶＰＭＶＡＴＶ（配列番号３０１）、ＣＳＧＧＧＧＳＧＧＧＧＲＡＮＬＶＰＭＶＡＴＶ（配列番号３０４）、ＣＳＧＧＧＧＳＧＧＧＧＡＡＰＶＡＮＬＶＰＭＶＡＴＶ（配列番号３０５）、ＣＳＧＧＧＧＳＧＧＧＧＫＱＬＲＶＶＮＧＡＮＬＶＰＭＶＡＴＶ（配列番号３０６）、ＣＳＧＧＧＧＳＧＧＧＧＳＳＫＹＱＡＮＬＶＰＭＶＡＴＶ（配列番号３０７）、ＣＳＧＧＧＧＳＧＧＧＧＧＧＧＧＦＡＮＬＶＰＭＶＡＴＶ（配列番号３０８）のいずれかを含む、請求項３４に記載の分子。
- 前記標的化部分が請求項２に記載のとおりである、および／または前記Ｔ細胞抗原が請求項３に記載のとおりである、請求項２８、２９および３２のいずれか一項に記載のパーツキット、請求項３０または３２に記載の医薬、請求項３１または３２に記載の標的化部分およびＴ細胞抗原、請求項３２または３３に記載の薬剤、ならびに請求項３４または３５に記載の分子。
- 前記切断部位が、請求項４または５に記載のとおり選択的に切断される、請求項２８、２９、３２または３６のいずれか一項に記載のパーツキット、請求項３０、３２および３６のいずれか一項に記載の医薬、請求項３１、３２または３６のいずれか一項に記載の標的化部分およびＴ細胞抗原、請求項３２、３３または３６に記載の薬剤、ならびに請求項３４〜３６のいずれか一項に記載の分子。
- 前記標的化部分およびＴ細胞抗原が、単一ペプチド鎖によってコードされている、請求項１〜１７、２２、２７、３２、３３、３６および３７のいずれか一項に記載の薬剤、請求項１８、２４、２６、２７および３２のいずれか一項に記載の組成物、請求項１９〜２１、２７および３２のいずれか一項に記載の医薬、ならびに請求項２３、２５、２７および３２のいずれか一項に記載の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1104514.3 | 2011-03-17 | ||
| GBGB1104514.3A GB201104514D0 (en) | 2011-03-17 | 2011-03-17 | Re-directed immunotherapy |
| GB1203434.4 | 2012-02-28 | ||
| GBGB1203434.4A GB201203434D0 (en) | 2012-02-28 | 2012-02-28 | Re-directed immunotherapy |
| PCT/GB2012/050577 WO2012123755A1 (en) | 2011-03-17 | 2012-03-15 | Re-directed immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017078724A Division JP6449933B2 (ja) | 2011-03-17 | 2017-04-12 | 再指向性免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509605A JP2014509605A (ja) | 2014-04-21 |
| JP2014509605A5 true JP2014509605A5 (ja) | 2015-05-07 |
| JP6130307B2 JP6130307B2 (ja) | 2017-05-17 |
Family
ID=46026856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558513A Expired - Fee Related JP6130307B2 (ja) | 2011-03-17 | 2012-03-15 | 再指向性免疫療法 |
| JP2017078724A Active JP6449933B2 (ja) | 2011-03-17 | 2017-04-12 | 再指向性免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017078724A Active JP6449933B2 (ja) | 2011-03-17 | 2017-04-12 | 再指向性免疫療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9402916B2 (ja) |
| EP (2) | EP3138581B1 (ja) |
| JP (2) | JP6130307B2 (ja) |
| CN (2) | CN110038135B (ja) |
| AU (2) | AU2012228100B2 (ja) |
| CA (1) | CA2830349C (ja) |
| DK (2) | DK3138581T3 (ja) |
| WO (1) | WO2012123755A1 (ja) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| CA2863695C (en) | 2012-02-16 | 2023-01-17 | Vlp Therapeutics, Llc | Virus like particle composition |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9118967B2 (en) * | 2012-08-17 | 2015-08-25 | Jamdeo Technologies Ltd. | Channel changer for intelligent television |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| CA2886120A1 (en) | 2012-10-08 | 2014-04-17 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| US9066928B1 (en) * | 2012-12-04 | 2015-06-30 | University Of Kentucky Research Foundation | Method, composition, and kit useful for treatment of alzheimer's disease |
| CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| MX2015015037A (es) | 2013-05-02 | 2016-07-08 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| JP6659535B2 (ja) | 2013-06-28 | 2020-03-04 | オークランド ユニサービシーズ リミティド | アミノ酸及びペプチド接合体及び接合方法 |
| GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| WO2015199618A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| US9546206B2 (en) | 2014-08-08 | 2017-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
| US9969986B2 (en) | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| EP3191589A4 (en) | 2014-09-11 | 2018-05-09 | VLP Therapeutics, LLC | Flavivirus virus like particle |
| US10640775B2 (en) * | 2014-09-30 | 2020-05-05 | Thena Biotech S.r.l. | Fusion protein, nanoparticle composed of a plurality of monomers of said fusion protein, and uses thereof |
| WO2016095783A1 (zh) * | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| JP2018505152A (ja) | 2014-12-23 | 2018-02-22 | アン ブリンブル マーガレット | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
| WO2016126611A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| WO2017023774A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Prodrugs of glutamine analogs |
| US10842763B2 (en) * | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
| WO2017023793A2 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods for cancer and immunotherapy using glutamine analogues, including don |
| WO2017079747A1 (en) | 2015-11-06 | 2017-05-11 | Regents Of The University Of Minnesota | Activation of resident memory t cells for cancer immunotherapy |
| ES2873846T3 (es) | 2015-11-19 | 2021-11-04 | Revitope Ltd | Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| CN105418766A (zh) * | 2015-12-22 | 2016-03-23 | 深圳市北科生物科技有限公司 | 一种用于免疫治疗的eb病毒lmp2a串联表位肽及其应用 |
| US20190048094A1 (en) * | 2016-02-24 | 2019-02-14 | Oncomed Pharmaceuticals, Inc. | Redirecting immune responses |
| KR20180128915A (ko) | 2016-02-26 | 2018-12-04 | 오클랜드 유니서비시즈 리미티드 | 아미노산 및 펩티드 접합체 및 접합 방법 |
| JP7281795B2 (ja) | 2016-04-07 | 2023-05-26 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 |
| AU2017354070A1 (en) | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
| BR112019008727A2 (pt) | 2016-11-28 | 2019-07-16 | Chugai Pharmaceutical Co Ltd | domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| US11555056B2 (en) | 2017-04-26 | 2023-01-17 | Mayo Foundation for Medical Education and Research and Board of Regents | Methods and materials for treating cancer |
| EP3630153A2 (en) * | 2017-05-22 | 2020-04-08 | National Hellenic Research Foundation | Macrocyclic modulators of disease associated protein misfolding and aggregation |
| KR20200027956A (ko) | 2017-06-23 | 2020-03-13 | 패쏘백스 엘엘씨 | 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도 |
| KR102190890B1 (ko) * | 2017-08-10 | 2020-12-15 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| EA202091178A1 (ru) * | 2017-12-20 | 2020-09-01 | Глаксосмитклайн Байолоджикалс Са | Антигенные конструкции на основе вируса эпштейна-барр |
| CN110151987B (zh) * | 2018-02-11 | 2023-10-13 | 汕头大学医学院 | 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途 |
| WO2019220209A1 (en) * | 2018-05-18 | 2019-11-21 | The Council Of The Queensland Institute Of Medical Research | Adoptive t-cell therapy for cmv infection and cmv-associated diseases |
| EP3816182A4 (en) * | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY |
| CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
| US11560408B2 (en) | 2018-12-27 | 2023-01-24 | Verimmune Inc. | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors |
| KR102552440B1 (ko) * | 2019-02-08 | 2023-07-11 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| US20220195441A1 (en) * | 2019-04-25 | 2022-06-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |
| JP2022542867A (ja) * | 2019-07-23 | 2022-10-07 | ドイチェス クレブスフォルシュンクスツェントルム | Ａｍｌの処置のためのポリペプチド |
| CN115667302A (zh) | 2020-02-06 | 2023-01-31 | 亚洲大学校产学协力团 | 将抗原衍生t细胞抗原表位或含所述表位的肽呈递到细胞表面的融合抗体及含所述融合抗体的组合物 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| IL302190A (en) | 2020-10-19 | 2023-06-01 | Verimmune Inc | Virus-induced preparations and methods for redirecting immune responses in the use of said preparations for cancer treatment |
| CN117222667A (zh) * | 2021-03-16 | 2023-12-12 | Jn生物科学有限责任公司 | 用于治疗免疫失调的双功能分子 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3578568A (en) | 1968-11-29 | 1971-05-11 | Atlantic Richfield Co | Purification of low molecular weight epoxides by extractive distillation with a glycol or glycol ether |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| EP0659438A1 (en) | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
| CZ292061B6 (cs) | 1994-03-17 | 2003-07-16 | Merck Patent Gmbh | Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
| US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5698679A (en) | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| DE69636015T2 (de) | 1995-05-03 | 2007-01-04 | Bioenhancementsments Ltd. | Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird |
| US20080286228A1 (en) * | 1995-10-20 | 2008-11-20 | Tarantolo Stefano R | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
| EP2057999A3 (en) | 1995-12-22 | 2009-07-29 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| CA2265476A1 (en) | 1996-09-12 | 1998-03-19 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| HRP970566A2 (en) | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
| GB9624993D0 (en) | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
| US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| ES2300122T3 (es) | 1997-03-20 | 2008-06-01 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | Anticuerpos recombinantes e inmunoconjugados dirigidos contra celulas y tumores portadores de cd-22. |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| JP4566290B2 (ja) | 1997-04-30 | 2010-10-20 | ツインストランド・ホールディングス・インコーポレイテッド | 癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体 |
| WO1999002175A1 (en) | 1997-07-10 | 1999-01-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| CA2323632A1 (en) | 1998-03-13 | 1999-09-16 | Epimmune Inc. | Hla-binding peptides and their uses |
| ES2207278T3 (es) | 1998-07-28 | 2004-05-16 | Micromet Ag | Heterominicuerpos. |
| US7399827B1 (en) | 1998-09-01 | 2008-07-15 | The United States Of America As Represented By The Department Of Health And Human Services | Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
| US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US6458552B1 (en) | 2000-06-06 | 2002-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Metalloprotease peptide substrates and methods |
| US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2002044197A2 (en) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
| PT1399483E (pt) | 2001-01-05 | 2010-07-20 | Pfizer | Anticorpos contra o receptor do factor i de crescimento tipo insulina |
| CA2715570A1 (en) | 2001-04-26 | 2002-11-07 | Biogen Idec Ma Inc. | Cripto blocking antibodies and uses thereof |
| CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| CN100475848C (zh) | 2001-05-18 | 2009-04-08 | 麒麟麦酒株式会社 | 抗trail-r抗体 |
| ATE468348T1 (de) | 2001-09-26 | 2010-06-15 | Government Of The Us Secretary | Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen |
| EP1451226A1 (en) | 2001-11-30 | 2004-09-01 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| EP1461082A4 (en) | 2001-12-03 | 2006-06-28 | Abgenix Inc | ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX) |
| BR0307216A (pt) | 2002-01-28 | 2005-12-20 | Medarex Inc | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) |
| EP2295468B1 (en) | 2002-02-14 | 2015-07-08 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| ES2373715T3 (es) | 2002-05-10 | 2012-02-08 | Medimmune, Llc | Anticuerpos monoclonales frente a epha2 y procedimientos de uso de los mismos. |
| ATE530577T1 (de) | 2002-05-10 | 2011-11-15 | Purdue Research Foundation | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| PT1545613E (pt) | 2002-07-31 | 2011-09-27 | Seattle Genetics Inc | Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| CN101658672B (zh) | 2002-10-08 | 2017-09-26 | 免疫医疗公司 | 用iii类抗cea单克隆抗体和治疗剂进行联合治疗 |
| HUE026914T2 (en) | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| AU2004210088A1 (en) | 2003-02-06 | 2004-08-19 | Micromet Ag | Trimeric polypeptide construct to induce an enduring T cell response |
| US7595379B2 (en) | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US10000574B2 (en) | 2003-11-28 | 2018-06-19 | Amgen Research (Munich) Gmbh | Compositions comprising polypeptides |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| KR20060129353A (ko) | 2003-12-31 | 2006-12-15 | 사노피 파스퇴르 인크 | 표적화된 면역원 |
| GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| CN102698267B (zh) | 2004-08-24 | 2017-07-21 | 中外制药株式会社 | 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法 |
| US20060045881A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| BRPI0515113A (pt) | 2004-09-10 | 2008-07-01 | Wyeth Corp | anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina |
| BRPI0518279A2 (pt) | 2004-10-26 | 2008-11-11 | Chugai Pharmaceutical Co Ltd | anticorpo antiglipicam 3 tendo cadeia de aÇécar modificada |
| CA2595398A1 (en) | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of b-cell malignancies |
| NZ556788A (en) | 2005-01-05 | 2011-03-31 | Biogen Idec Inc | Humanized CRIPTO binding molecules with CDRs from murine B3F6 |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| CA2597638A1 (en) * | 2005-02-16 | 2006-08-24 | University Of Zuerich | Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9 |
| NZ560414A (en) | 2005-02-18 | 2011-04-29 | Medarex Inc | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| CN101300355A (zh) | 2005-10-13 | 2008-11-05 | 威瑞克斯医药公司 | 包含丙型肝炎病毒多肽和用于引起免疫应答的Fc片段的嵌合抗原 |
| ATE458000T1 (de) | 2005-11-18 | 2010-03-15 | Dabur Pharma Ltd | Zielgerichtete fusionsproteine für die krebstherapie |
| EP1790358A1 (en) | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Protein constructs designed for targeting and lysis of cells |
| CA2632094C (en) | 2005-12-02 | 2015-01-27 | Wayne A. Marasco | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| CN105753983A (zh) | 2005-12-13 | 2016-07-13 | 阿斯利康(瑞典)有限公司 | 胰岛素样生长因子特异性结合蛋白及其用途 |
| EP3085373A1 (en) | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Immune response modifier conjugates |
| EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| GB0605702D0 (en) | 2006-03-21 | 2006-05-03 | Biotransformations Ltd | Materials and methods for immune cell stimulation |
| US8101727B2 (en) | 2006-03-30 | 2012-01-24 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
| EA200870555A1 (ru) * | 2006-05-19 | 2009-04-28 | Тева Фармасьютикал Индастриз, Лтд. | Слитые белки, их применение и способы их получения |
| US8993295B2 (en) * | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| WO2008019366A2 (en) | 2006-08-07 | 2008-02-14 | Ludwig Institute For Cancer Research | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
| CA2668017A1 (en) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Improved conjugates |
| AU2007333485A1 (en) | 2006-10-31 | 2008-06-19 | Immunogen, Inc. | Methods for improving antibody production |
| WO2008063113A1 (en) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf |
| EP2423222B2 (en) | 2007-01-30 | 2020-07-29 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| JP5377330B2 (ja) | 2007-02-02 | 2013-12-25 | ベイラー リサーチ インスティテュート | 抗原提示細胞上に発現されたｄｃｉｒへの抗原のターゲティングに基づくワクチン |
| US8889117B2 (en) | 2007-02-15 | 2014-11-18 | Yale University | Modular nanoparticles for adaptable vaccines |
| CA2682296C (en) | 2007-04-04 | 2017-02-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anti-epcam antibody and uses thereof |
| AR066476A1 (es) | 2007-05-08 | 2009-08-19 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos |
| WO2008144029A1 (en) | 2007-05-14 | 2008-11-27 | The University Of Chicago | Antibody-light fusion products for cancer therapeutics |
| BRPI0721707A2 (pt) | 2007-05-17 | 2013-01-15 | Genentech Inc | estruturas de cristal de fragmentos de neuropilina e complexos de neuropilina-anticorpo |
| GB0716160D0 (en) | 2007-08-17 | 2007-09-26 | Biotransformations Ltd | Materials and methods for treating cancers which express folate receptors |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| CA2698146C (en) | 2007-08-30 | 2016-12-20 | Daiichi Sankyo Company, Limited | Anti-epha2 antibody |
| CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US9023351B2 (en) | 2007-11-26 | 2015-05-05 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses thereof |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| WO2010001585A1 (en) | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| SI2352763T2 (sl) | 2008-10-01 | 2022-11-30 | Amgen Research (Munich) Gmbh | Bispecifična enoverižna protitelesa s specifičnostjo za tarčne antigene z visoko molekulsko maso |
| RU2011127198A (ru) | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | Иммуноглобулины с двойными вариабельными доменами и их применение |
| JP2012511033A (ja) * | 2008-12-08 | 2012-05-17 | テゴファーム コーポレーション | 多価化合物の可逆阻害用マスキングリガンド |
| CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
| MX2011009281A (es) | 2009-03-06 | 2012-07-30 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12. |
| CN105884903B (zh) | 2009-03-10 | 2019-12-06 | 贝勒研究院 | 靶向抗原呈递细胞的疫苗 |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| CN102573902A (zh) | 2009-11-05 | 2012-07-11 | 分子医学和免疫学中心 | 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物 |
| JP6066732B2 (ja) | 2010-03-05 | 2017-01-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的免疫調節抗体および融合タンパク質に基づく組成物および方法 |
| MX2012010481A (es) | 2010-03-11 | 2012-10-09 | Rinat Neuroscience Corp | Anticuerpos con union de antigenos dependiente del ph. |
| PT2552959T (pt) | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| CN103002879B (zh) | 2010-07-01 | 2016-04-20 | 阿昂梅迪克斯公司 | 来自细胞原生质体的微泡及其应用 |
| WO2012031609A1 (en) | 2010-09-07 | 2012-03-15 | Johannes Kepler Universität Linz | Biodegradable, water soluble and ph responsive poly(organo)phosphazenes |
| GB201019118D0 (en) | 2010-11-11 | 2010-12-29 | King S College | Conjugates and their uses in molecular imaging |
| EP3138581B1 (en) * | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| CA2892371C (en) | 2011-12-01 | 2021-01-19 | The Brigham And Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US10040827B2 (en) | 2012-03-19 | 2018-08-07 | Deutsches Krebsforschungszentrum | B-cell receptor complex binding proteins containing T-cell epitopes |
| WO2014043523A1 (en) * | 2012-09-14 | 2014-03-20 | The Johns Hopkins University | Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| KR102272213B1 (ko) * | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
| WO2016131856A1 (en) * | 2015-02-18 | 2016-08-25 | F. Hoffmann-La Roche Ag | Immunoconjugates for specific induction of t cell cytotoxicity against a target cell |
-
2012
- 2012-03-15 EP EP16191609.3A patent/EP3138581B1/en active Active
- 2012-03-15 AU AU2012228100A patent/AU2012228100B2/en active Active
- 2012-03-15 CA CA2830349A patent/CA2830349C/en active Active
- 2012-03-15 CN CN201811559481.4A patent/CN110038135B/zh not_active Expired - Fee Related
- 2012-03-15 WO PCT/GB2012/050577 patent/WO2012123755A1/en active Application Filing
- 2012-03-15 EP EP12718715.1A patent/EP2686020B1/en active Active
- 2012-03-15 DK DK16191609.3T patent/DK3138581T3/en active
- 2012-03-15 JP JP2013558513A patent/JP6130307B2/ja not_active Expired - Fee Related
- 2012-03-15 US US14/005,452 patent/US9402916B2/en active Active
- 2012-03-15 DK DK12718715.1T patent/DK2686020T3/en active
- 2012-03-15 CN CN201280024084.1A patent/CN103561771B/zh active Active
-
2015
- 2015-03-17 US US14/660,137 patent/US9358282B2/en active Active
- 2015-12-16 US US14/972,059 patent/US10287321B2/en not_active Expired - Fee Related
-
2016
- 2016-11-16 AU AU2016259343A patent/AU2016259343B2/en active Active
-
2017
- 2017-04-12 JP JP2017078724A patent/JP6449933B2/ja active Active
-
2019
- 2019-03-27 US US16/366,240 patent/US11236131B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509605A5 (ja) | ||
| US11911466B2 (en) | Substituted pyrimidines as vaccine adjuvants | |
| Sadeghzadeh et al. | Dendritic cell therapy in cancer treatment; the state-of-the-art | |
| Zhou et al. | Different-sized gold nanoparticle activator/antigen increases dendritic cells accumulation in liver-draining lymph nodes and CD8+ T cell responses | |
| Melief et al. | Therapeutic cancer vaccines | |
| Conroy et al. | TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours | |
| Zom et al. | Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates | |
| CN110038135B (zh) | 重新定向的免疫治疗 | |
| Zom et al. | TLR ligand–peptide conjugate vaccines: toward clinical application | |
| US20170326232A1 (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
| Chen et al. | A simple but effective cancer vaccine consisting of an antigen and a cationic lipid | |
| Yaddanapudi et al. | Cancer vaccines: Looking to the future | |
| Garu et al. | Genetic immunization with in vivo dendritic cell-targeting liposomal DNA vaccine carrier induces long-lasting antitumor immune response | |
| Li et al. | Manganese coordination micelles that activate stimulator of interferon genes and capture in situ tumor antigens for cancer metalloimmunotherapy | |
| Chang et al. | Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy | |
| CN112601554A (zh) | 肿瘤微环境活化的药物-结合剂缀合物和与其相关的用途 | |
| Platten et al. | Microenvironmental clues for glioma immunotherapy | |
| Jemon et al. | An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy | |
| Cools et al. | Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? | |
| Schijns et al. | Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines | |
| Fang et al. | The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization | |
| Speir et al. | Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins | |
| Speir et al. | Engaging natural killer T cells as ‘Universal Helpers’ for vaccination | |
| Llopiz et al. | Enhancement of antitumor vaccination by targeting dendritic cell-related IL-10 | |
| Koido et al. | Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions |